Alvespimycin
Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 nM.
Product Specifications
CAS Number
467214-20-6
Product Name Alternative
17-DMAG; KOS-1022; NSC 707545
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
HSP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/alvespimycin.html
Purity
99.52
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C/C1=C\C=C/[C@@H]([C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC(C(C(NC1=O)=CC2=O)=O)=C2NCCN(C)C)C)OC)O[H])C)OC(N)=O)OC
Molecular Formula
C32H48N4O8
Molecular Weight
616.75
Precautions
H315, H319, H335
References & Citations
[1]Ge J, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem. 2006 Jul 27;49 (15) :4606-15.|[2]Hertlein E, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010 Jul 8;116 (1) :45-53.|[3]Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel) . 2016 Aug 24;8 (9) . pii: E77.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
HSP90
Citation 01
ACS Biomater Sci Eng. 2021 Nov 8;7 (11) :5154-5164.|Adv Sci (Weinh) . 2025 Jul 29:e01977.|Cell Death Dis. 2022 Jan 21;13 (1) :73.|Exp Ther Med. 2022 Apr;23 (4) :273.|Friedrich-Alexander University Erlangen-Nuremberg. 2016 Sep 14.|NPJ Precis Oncol. 2023 May 18;7 (1) :44.|Pharmacol Res. 2020 Jan;151:104512.|Sci Rep. 2021 May 26;11 (1) :11057.|Theranostics. 2020 Jul 9;10 (18) :8415-8429.|Authorea. April 10, 2021.|Biochim Biophys Acta Mol Cell Res. 2024 Apr;1871 (4) :119703.|bioRxiv. 2021 Jan 27.|Br J Pharmacol. 2021 Nov;178 (22) :4485-4500.|Drug Deliv Transl Res. 2025 Oct 29.|Front Pharmacol. 2022 Jan 14:12:724192.|Nat Commun. 2021 Jul 22;12 (1) :4457.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
